No­vavax grabs an­oth­er CFO while Pat Cotro­neo re­tires from Fi­bro­Gen; Eli Lil­ly re­assem­bles key staff af­ter bio­med­i­cines unit split

→ The peren­ni­al Char­lie Brown of vac­cine de­vel­op­ment, No­vavax is grap­pling with Lucy’s knack for pulling the foot­ball away once again, this time with its Covid-19 vac­cine as the FDA pushed back an­oth­er bid for an EUA ear­li­er this month. In the mean­time, No­vavax has found Jim Kel­ly to re­place Greg Covi­no as CFO, leav­ing John Trizzi­no one less C-suite ti­tle to jug­gle. Kel­ly, the ex-CFO at Van­da Phar­ma­ceu­ti­cals, was just in this space in Oc­to­ber 2020 when he suc­ceed­ed Greg Patrick as CFO of Su­per­nus, and now he makes a quick change to a biotech that can’t seem to avoid tak­ing on Sisyphean qual­i­ties no mat­ter what it does.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Venture & Research Associate

Alexandria Real Estate Equities

San Francisco, CA, USA